Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06783062

Activation Failure of Knee Extensors After Anterior Cruciate Ligament Rupture Depending on the Contraction Mode

The primary objective of the study is to evaluate the impact of ACL injury and ACL reconstruction on voluntary activation during maximal voluntary contraction (measured by neurophysiological parameters) according to the contraction mode.

The goal is to provide elements of knowledge to clinicians about the mechanisms of the activation failure depending on contraction mode, but also the resulting adapted clinical recommendations for conducting rehabilitation, and particularly for the use of different contraction modes.

The main hypothesis is that activation failure is not equal according to the contraction mode during maximal voluntary contractions and neurophysiological parameters will be decreased in comparison with non-injured subjects.

Secondary objectives are:

* To analyze the evolution of neurophysiological parameters between sessions interspaced by several months according to the contraction mode. * To observe this time evolution depending on the treatment strategy chosen: rehabilitation or surgery plus rehabilitation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A. ACL-injured groups (surgically or conservatively treated):

  • Age between 18 and 50 years
  • Free, informed consent signed by the participant and the investigator.
  • Session 1: Delay of 2 to 6 weeks after injury, with a quiet knee (range of motion 110- 0°, minimal effusion, maximal contraction pain ≤ 2/10)
  • Session 2: Duration of 36 to 42 weeks after injury, with a quiet knee (range of motion 110-0°, minimal effusion, maximal contraction pain ≤ 2/10)
  • Independent person (Unprotected: under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision)

B. ControlGroup:

  • Age between 18 and 50 years
  • Free, informed consent signed by the participant and the investigator.
  • Sport practitioners: at least once per week practicing activities like collective sports, racket sports, combat sports, skiing, or on-loading activities with changing of directions.
  • Independent person (Unprotected: under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision)

Exclusion criteria

  • 1. Subjects fitted with an implanted electronic device such as a cardiac pacemaker 2. Professional athlete 3. Pregnant women 4. Subject with systemic pathology or treatment affecting the musculoskeletal system 5. Subject with a history of neurological pathology or traumatic pathology, or pathology that required orthopedic treatment and/or surgery of the knee, hip and/or lumbar spine 6. Contraindication to isokinetic testing: incapacitating pain, evolving pathological process, non- healed fracture, unbalanced cardiovascular pathology (angina pectoris, arterial hypertension) 7. Contralateral knee injury 8. Subject inability to follow procedures or insufficient knowledge of project language 9. Data acquisition issue or injury during testing

Treatment and study plan

Primary outcomes

  1. Voluntary Activation Level

    Time frame: Between 2 and 6 weeks after ACL rupture

Secondary outcomes

  1. Maximal voluntary torque

    Time frame: between 2 to 6 weeks after ACL rupture

  2. EMG activity of vastus lateralis, vastus medialis and rectus femoris

    Time frame: between 2 to 6 weeks after ACL rupture

    Quantified with root mean square (RMS), normalized to the maximal M-wave

  3. Voluntary Activation Level

    Time frame: Around 9 months after ACL rupture

  4. Maximal voluntary torque

    Time frame: Around 9 months after ACL rupture

  5. EMG activity of vastus lateralis, vastus medialis and rectus femoris

    Time frame: Around 9 months after ACL rupture

Study contacts

Contact information is provided by the study sponsor or research team.

François Fourchet, PhD

CONTACT

[email protected]

Simon Barrué-Belou, PhD

CONTACT

[email protected]

+41 22 719 78 92

Sponsors and collaborators

Lead sponsor

La Tour Hospital

Other

Collaborators

  • Toulouse NeuroImaging Center (ToNIC - UMR 1214 Inserm/UPS)

Registry information

Acronym: QUADFAIL

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 20, 2025
Registry last updated
Jan 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.